Drug intelligence / Profile preview

AI201901

Development stage: Phase 3
Lead developer: Abdi Ibrahim
Modality: Vaccines & Immunotherapeutics
Administration: Intranasal

Overview

AI201901 is an investigational drug developed by Abdi Ibrahim for the treatment of allergic rhinitis. It is being evaluated as a novel therapy and has reached Phase III clinical trials in Turkey, where it is administered intranasally as a spray. The precise mechanism of action remains undefined in public sources, but some databases list its modality as a vaccine, suggesting it may act through immunomodulation rather than traditional antihistaminic pathways. As of the latest updates, there are no approved indications or known adverse events reported for this agent.

Beyond the preview

Go deeper on AI201901.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AI201901.

Explore the full profile